Human papillomavirus prevalence among women with cervical intraepithelial neoplasia III and invasive cervical cancer from Goiânia, Brazil

Optimizing the management of patients with HPV-associated cervical diseases remains a priority for the modern studies on this issue. The human papillomavirus is divided into two types: high-risk and low-risk types according to its malignant potential to cause cervical cancer and some other oncological diseases. Human papillomavirus can clear spontaneously in 85-90% cases, but the risk of cervical intraepithelial neoplasia and invasive cervical cancer is quite high in persistent high-risk oncogenic infection. The virus presence in the body tissues cannot be considered as a marker for progression or regression of the pathological process in the strict sense, even though cervical intraepithelial neoplasia and cervical cancer develop in HPV-positive patients in the vast majority of cases. These studies are aimed at searching for the new and improving existing methods for early diagnosis of precancerous diseases and cervical cancer. The development of the HPV-associated pathological process is known to be dependent on the human immune system status. The virus provokes a cellular immune response, which is expressed as changes in interferon status, cytotoxic activity of natural killer cells, methylation processes, etc. The use of a holistic approach to treatment, a comdoibination of traditional therapy, antigen-specific vaccination and administration of immunomodulating agents seems relevant for patients with persistent high-risk oncogenic papilloma virus, as well as precancerous diseases and cervical cancer. The use of immunomodulators in the complex treatment of virus-associated diseases contributes to relief of symptoms and reduction of the recurrence rate.

Download Full-text

Human Papillomavirus Type Distribution in Cervical Intraepithelial Neoplasia Grade 2/3 and Cervical Cancer in Portugal: A CLEOPATRE II Study

International Journal of Gynecological Cancer ◽

10.1097/igc.0b013e318280f26e ◽

2013 ◽

Vol 23 (3) ◽

pp. 500-506 ◽

Cited By ~ 13

Author(s):

Angela Pista ◽

Carlos Freire de Oliveira ◽

Carlos Lopes ◽

Maria João Cunha

Keyword(s):

Cervical Cancer ◽

Human Papillomavirus ◽

High Risk ◽

Cervical Intraepithelial Neoplasia ◽

Invasive Cervical Cancer ◽

Intraepithelial Neoplasia ◽

Multiple Infections ◽

Hpv 16 ◽

Specific Distribution ◽

Hpv Genotypes

ObjectiveCervical cancer is the third most frequent cancer in women, worldwide and etiologically associated with infection by human papillomavirus (HPV). Following the results of the first epidemiologic population-based CLEOPATRE study in Portugal, it was important to understand the HPV type-specific distribution in women with cervical intraepithelial neoplasia (CIN) grades 2 and 3 and invasive cervical cancer (ICC).MethodsThis was an observational, multicenter, cross-sectional study with retrospective data collection. Between January 2008 and May 2009, paraffin-embedded samples of histologically confirmed cases of CIN2, CIN3, and ICC were collected from the 5 regional health administrations in mainland Portugal. Eligible samples were sent to 2 central laboratories for histological reassessment and HPV genotyping. Prevalence estimates were calculated together with 95% confidence intervals.ResultsA total of 582 samples, 177 cases of CIN2, 341 of CIN3, and 64 of ICC, were included. The mean age of participants was 41.8 years (range, 20–88 years). The overall HPV prevalence was 97.9% with a higher prevalence of high-risk genotypes, particularly HPV 16. Multiple infections were observed in 11.2% of the cases. Human papillomavirus prevalence was 95.5% in CIN2, 99.4% in CIN3, and 96.9% in ICC. The 8 more frequent genotypes in order of decreasing frequency were HPV 16, 31, 58, 33, 51, 52, 18, and 35 in CIN2 and HPV 16, 31, 33, 58, 52, 35, 18, and 51 in CIN3. In ICC cases, the 12 detected HPV genotypes were HPV 16, 18, 31, 33, 45, 51, 52, 53, 56, 58, 59, and 73. However, HPV 53 and 73 were always associated to other high-risk genotypes. Human papillomavirus types 31, 51, 52, 56, and 59 were detected in 1 case each.ConclusionsHuman papillomavirus prevalence and patterns of type-specific HPV positivity were comparable with other studies. Current HPV vaccines should protect against HPV genotypes responsible for 77.4% of ICC in Portugal.

Download Full-text

Kanker serviks dan gen Fas-promoter-670

Jurnal Biomedika dan Kesehatan ◽

10.18051/jbiomedkes.2019.v2.90-91 ◽

2019 ◽

Vol 2 (3) ◽

pp. 90-91

Author(s):

ML Edy Parwanto

Keyword(s):

Cervical Cancer ◽

Human Papillomavirus ◽

Cervical Intraepithelial Neoplasia ◽

Incidence Rate ◽

Invasive Cervical Cancer ◽

Intraepithelial Neoplasia ◽

Low Grade ◽

High Grade ◽

Squamous Intraepithelial Lesion ◽

Intraepithelial Lesion

Kanker serviks merupakan keganasan pada serviks. Jenis kanker tersebut terjadi pada perempuan dan masih menjadi masalah di Indonesia. Indonesia merupakan negara urutan ke 4 di Asia Tenggara dengan insiden kanker serviks terbesar setelah Kamboja, Myanmar dan Thailand. Berdasar data statistik tahun 2012, tingkat insidensi (incidence rate) kanker serviks di Indonesia 17 per 100.000 perempuan per tahun.(1) Telah terbukti bahwa penyebab primer terjadinya kanker serviks yaitu virus papilloma atau yang lebih dikenal dengan istilah “human papillomavirus (HPV)”. Terdapat beberapa jenis serotype HPV, tetapi tidak semua jenis serotype bersifat progesif menjadikan kanker serviks. Salah satu serotype yang bersifat progesif menjadikan kanker serviks yaitu HPV serotype 16. HPV serotype 16 mampu mengubah sel epitel squamosa serviks (cervical-squamous-epithelial cells=CSEC) normal menjadi lesi intraepitelial squamosa tingkat rendah (low-grade squamous intraepithelial lesion=LSIL) atau neoplasia intraepitel serviks (cervical intraepithelial neoplasia=CIN) 1. Selanjutnya, LSIL atau CIN 1 berkembang menjadi lesi intraepitelial squamosa tingkat tinggi (high-grade squamous intraepithelial lesion=HSIL) atau CIN 2, dan akhirnya menjadi kanker serviks yang invasif (invasive cervical cancer=CIN3).(2)

Download Full-text